Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 357,074
  • Shares Outstanding, K 106,272
  • Annual Sales, $ 63,210 K
  • Annual Income, $ -120,550 K
  • 60-Month Beta 1.02
  • Price/Sales 1.16
  • Price/Cash Flow N/A
  • Price/Book 2.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.75
  • Number of Estimates 2
  • High Estimate -0.71
  • Low Estimate -0.80
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -368.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.27 +2.75%
on 01/24/20
4.47 -24.83%
on 01/16/20
-0.89 (-20.94%)
since 12/24/19
3-Month
2.51 +33.86%
on 12/02/19
5.33 -36.96%
on 12/10/19
-0.29 (-7.95%)
since 10/24/19
52-Week
1.13 +198.67%
on 08/02/19
8.39 -59.95%
on 03/13/19
-1.21 (-26.48%)
since 01/24/19

Most Recent Stories

More News
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl's Antiproliferative Effects in Patients With Carcinoid Syndrome

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO's(telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American...

LXRX : 3.36 (-2.33%)
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO(telotristat ethyl) will be presented at the American Society for Clinical Oncology (ASCO) 2020...

LXRX : 3.36 (-2.33%)
Neuroendocrine Carcinoma Market is projected to grow at a high 7.7% CAGR throughout 2017-2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 225.59 (-4.02%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.63 (-2.53%)
HCM : 23.48 (+1.47%)
LXRX : 3.36 (-2.33%)
NVS : 93.87 (-1.11%)
TEVA : 10.10 (-2.79%)
VRX.TO : 30.80 (-3.33%)
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

JPM : 133.15 (-2.48%)
LXRX : 3.36 (-2.33%)
Watch for Lexicon Pharmace to Potentially Rebound After Falling 4.99% Yesterday

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $4.08 to a high of $4.32. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $4.16...

LXRX : 3.36 (-2.33%)
Thinking about buying stock in Advanced Micro Devices, Best Buy, Canopy Growth Corp, Lexicon Pharmaceuticals, or Electrameccanica Vehicles?

InvestorsObserver issues critical PriceWatch Alerts for AMD, BBY, CGC, LXRX, and SOLO.

AMD : 50.35 (-2.63%)
BBY : 89.44 (-0.42%)
CGC : 22.65 (-7.78%)
SOLO : 2.21 (-3.07%)
LXRX : 3.36 (-2.33%)
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista(TM)) in type 2 diabetes. The topline results are as follows:

LXRX : 3.36 (-2.33%)
Lexicon Pharmace Set to Possibly Rebound After Yesterday's Selloff of 1.20%

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $4.48 to a high of $4.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $4.65...

LXRX : 3.36 (-2.33%)
Neuroendocrine Carcinoma Market is Anticipated to Expand at a Healthy CAGR of 7.7% During the Forecast Period 2017 – 2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 225.59 (-4.02%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.63 (-2.53%)
HCM : 23.48 (+1.47%)
LXRX : 3.36 (-2.33%)
NVS : 93.87 (-1.11%)
TEVA : 10.10 (-2.79%)
VRX.TO : 30.80 (-3.33%)
Implied Volatility Surging for Lexicon (LXRX) Stock Options

Investors need to pay close attention to Lexicon (LXRX) stock based on the movements in the options market lately.

LXRX : 3.36 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade LXRX with:

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

2nd Resistance Point 3.59
1st Resistance Point 3.48
Last Price 3.36
1st Support Level 3.26
2nd Support Level 3.15

See More

52-Week High 8.39
Fibonacci 61.8% 5.61
Fibonacci 50% 4.76
Fibonacci 38.2% 3.90
Last Price 3.36
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar